Resistance to Aromatase Inhibitors in Breast Cancer

The book brings together current knowledge about molecular and clinical aspects of resistance to aromatase inhibitors (AIs). The topics and features include: The history of development and clinical role of aromatase inhibitors in breast cancer. The structure and function of aromatase gene and protei...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Άλλοι συγγραφείς: Larionov, Alexey (Επιμελητής έκδοσης)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Cham : Springer International Publishing : Imprint: Springer, 2015.
Σειρά:Resistance to Targeted Anti-Cancer Therapeutics, 8
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 03675nam a22004695i 4500
001 978-3-319-17972-8
003 DE-He213
005 20151204183002.0
007 cr nn 008mamaa
008 150425s2015 gw | s |||| 0|eng d
020 |a 9783319179728  |9 978-3-319-17972-8 
024 7 |a 10.1007/978-3-319-17972-8  |2 doi 
040 |d GrThAP 
050 4 |a RC261-271 
072 7 |a MJCL  |2 bicssc 
072 7 |a MED062000  |2 bisacsh 
082 0 4 |a 614.5999  |2 23 
245 1 0 |a Resistance to Aromatase Inhibitors in Breast Cancer  |h [electronic resource] /  |c edited by Alexey Larionov. 
264 1 |a Cham :  |b Springer International Publishing :  |b Imprint: Springer,  |c 2015. 
300 |a XVI, 288 p. 56 illus., 27 illus. in color.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a Resistance to Targeted Anti-Cancer Therapeutics,  |x 2196-5501 ;  |v 8 
520 |a The book brings together current knowledge about molecular and clinical aspects of resistance to aromatase inhibitors (AIs). The topics and features include: The history of development and clinical role of aromatase inhibitors in breast cancer. The structure and function of aromatase gene and protein, including tissue-specific splicing and regulation of the gene, crystal structure of the enzyme, functioning of its active site and structural basis for development of new aromatase inhibitors. Experimental and pre-clinical models of resistance to aromatase inhibitors (including cell lines and xenografts) as well as methods and results of measuring oestrogen concentrations in blood and tumour tissue of breast cancer patients. Diversity of molecular mechanisms of AI resistance, including (i) ligand-independent signalling through oestrogen receptor pathway, (ii) hypersensitivity to low concentrations of oestrogens, (iii) crosstalk with non-endocrine signalling (including PI3K/mTOR, IGF, GDNF and Myc pathways), (iv) involvement of oestrogen-induced apoptosis and tissue microenvironment (including inflammatory immune cells and adipocytes) as well as (v) the role of epigenetic mechanisms and pioneering factors in ER signalling and AI resistance. Molecular markers and multi-gene signatures to predict response to AIs, clinical trials aimed at preventing or overcoming resistance by combining AIs with novel targeted agents (including AI combinations with HER2, EGFR, mTOR, PI3K, Akt, CDK4/6, FGFR, HDAC, IGF-1, Src, proteosome- and angiogenic- targeting agents). A review of the effects and clinical indications of aromatase inhibitors beyond breast cancer. Many of the chapters provide extensive historical overviews to connect current knowledge with the history and inner logic of the field. The authors’ team includes world-leading experts, making the book an essential resource for scientists developing new treatments for breast cancer and for medics treating breast cancer patients with aromatase inhibitors. 
650 0 |a Medicine. 
650 0 |a Cancer research. 
650 0 |a Drug resistance. 
650 0 |a Molecular biology. 
650 1 4 |a Biomedicine. 
650 2 4 |a Cancer Research. 
650 2 4 |a Drug Resistance. 
650 2 4 |a Molecular Medicine. 
700 1 |a Larionov, Alexey.  |e editor. 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
776 0 8 |i Printed edition:  |z 9783319179711 
830 0 |a Resistance to Targeted Anti-Cancer Therapeutics,  |x 2196-5501 ;  |v 8 
856 4 0 |u http://dx.doi.org/10.1007/978-3-319-17972-8  |z Full Text via HEAL-Link 
912 |a ZDB-2-SBL 
950 |a Biomedical and Life Sciences (Springer-11642)